10-K/A: BeiGene Files Amendment to 2024 Annual Report to Include Conformed Signature
10-K/A Amendment
BeiGene, Ltd. files an amendment to its 2024 Annual Report on Form 10-K solely to include the conformed signature of the company's current principal accounting officer.
Summary
- BeiGene, Ltd. is filing Amendment No. 1 to its Annual Report on Form 10-K for the year ended December 31, 2024.
- The amendment is solely for the purpose of inserting the conformed signature of the company's current principal accounting officer, which was inadvertently omitted from the original filing.
- No other changes have been made to the Form 10-K, and the amendment does not reflect events occurring after the initial filing on February 27, 2025.
- The amendment includes new certifications by the company's principal executive officer and principal financial officer.
- As of June 28, 2024, the aggregate market value of the ordinary shares held by non-affiliates was approximately $8.7 billion.
- As of February 14, 2025, there were 1,387,367,704 ordinary shares outstanding, including those held as ADSs and RMB shares.
Sentiment
Score: 7
Explanation: The document is a routine amendment for compliance purposes, indicating a neutral to slightly positive sentiment as it reflects adherence to regulatory requirements.
Management Comments
- John V. Oyler, Chief Executive Officer and Chairman, certified the report.
- Aaron Rosenberg, Chief Financial Officer, certified the report.
Industry Context
This is a standard regulatory filing update, ensuring compliance with SEC requirements for accurate and complete financial reporting.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Principal Accounting Officer | Not specified | Titus Ball | February 28, 2025 | To include the conformed signature of the company's current principal accounting officer, which was inadvertently omitted from the Form 10-K. |
Stakeholder Impact
- The amendment ensures accurate and complete financial reporting, which benefits shareholders by providing reliable information for investment decisions.
Next Steps
- The registrant intends to file a definitive proxy statement pursuant to Regulation 14A within 120 days of the end of the fiscal year ended December 31, 2024.
Key Dates
| Date | Description |
|---|---|
| June 28, 2024 | Date used to calculate the aggregate market value of ordinary shares held by non-affiliates. |
| December 31, 2024 | End of the fiscal year for the Annual Report on Form 10-K. |
| February 14, 2025 | Date for outstanding ordinary share count. |
| February 27, 2025 | Date of original Form 10-K filing. |
| February 28, 2025 | Date of Amendment No. 1 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.